Association of Afamin Concentration with Type 1 and Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.21271/ZJPAS.33.5.8Keywords:
Serum afamin, type 1 DM, type 2 DMAbstract
Afamin is a protein in humans that plays a major role in the regulation of glucose metabolism, insulin sensitivity, so it may be related to diabetes mellitus. The aim of this study to evaluate the afamin concentration level in diabetic patients. This study was a case-control study blood samples were collected from 130 patients of Diabetes mellitus (DM) which divided into two groups (65 types1 DM and 65 type 2 DM) from Laila Qasim center for diabetes in Erbil City. In addition90 healthy volunteers used as a control. Serum was separated to determine afamin concentration. The results showed that the level of afamin in type 2 diabetic patients were significantly higher than those of healthy adults (75.09 + 10.09 mg/L), and (65.62 + 7.18 mg/L) respectively, No significant differences in the concentration of afamin were observed between control and type 1 DM were (58.47 ± 8.13), and (63.07 ± 5.53) respectively. Our finding showed that increase serum afamin concentration in type 2 diabetes patients can be used as a biomarker for predicting diabetes mellitus.
References
COMPANY, F. T. 2020. Human AFM(Afamin) ELISA Kit [Online]. Available: https://www.fn-test.com/product/eh2493/ [Accessed].
DELHI, N. J. R. T. O. D. M. N. E. N. D. N. D. J. B. M. P. 2012. textbook of diabetes mellitus. 2nd ed, Jaypee Brothers Medical Publishers
DI LEO, G. & SARDANELLI, F. J. E. R. E. 2020. Statistical significance: p value, 0.05 threshold, and applications to radiomics—reasons for a conservative approach. 4, 1-8.
JERKOVIC, L., VOEGELE, A. F., CHWATAL, S., KRONENBERG, F., RADCLIFFE, C. M., WORMALD, M. R., LOBENTANZ, E. M., EZEH, B., ELLER, P., DEJORI, N., DIEPLINGER, B., LOTTSPEICH, F., SATTLER, W., UHR, M., MECHTLER, K., DWEK, R. A., RUDD, P. M., BAIER, G. & DIEPLINGER, H. 2005. Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression. J Proteome Res, 4, 889-99.
KOLLERITS, B., LAMINA, C., HUTH, C., MARQUES-VIDAL, P., KIECHL, S., SEPPALA, I., COOPER, J., HUNT, S. C., MEISINGER, C., HERDER, C., KEDENKO, L., WILLEIT, J., THORAND, B., DAHNHARDT, D., STOCKL, D., WILLEIT, K., RODEN, M., RATHMANN, W., PAULWEBER, B., PETERS, A., KAHONEN, M., LEHTIMAKI, T., RAITAKARI, O. T., HUMPHRIES, S. E., VOLLENWEIDER, P., DIEPLINGER, H. & KRONENBERG, F. 2017. Plasma Concentrations of Afamin Are Associated With Prevalent and Incident Type 2 Diabetes: A Pooled Analysis in More Than 20,000 Individuals. Diabetes Care, 40, 1386-1393.
KONINGER, A., MATHAN, A., MACH, P., FRANK, M., SCHMIDT, B., SCHLEUSSNER, E., KIMMIG, R., GELLHAUS, A. & DIEPLINGER, H. 2018. Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study. Reprod Biol Endocrinol, 16, 30.
KRONENBERG, F. & DIEPLINGER, H. J. C. L. 2015. Afamin is a promising novel marker for metabolic syndrome and related diseases. Clinical Lipidology, 10, 207-3.
KRONENBERG, F., KOLLERITS, B., KIECHL, S., LAMINA, C., KEDENKO, L., MEISINGER, C., WILLEIT, J., HUTH, C., WIETZORREK, G., ALTMANN, M. E., THORAND, B., MELMER, A., DAHNHARDT, D., SANTER, P., RATHMANN, W., PAULWEBER, B., KOENIG, W., PETERS, A., ADHAM, I. M. & DIEPLINGER, H. 2014. Plasma concentrations of afamin are associated with the prevalence and development of metabolic syndrome. Circ Cardiovasc Genet, 7, 822-9.
LESLIE, R. D., PALMER, J., SCHLOOT, N. C. & LERNMARK, A. J. D. 2016. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. 59, 13-20.
LICHENSTEIN, H. S., LYONS, D. E., WURFEL, M. M., JOHNSON, D. A., MCGINLEY, M. D., LEIDLI, J. C., TROLLINGER, D. B., MAYER, J. P., WRIGHT, S. D. & ZUKOWSKI, M. M. 1994. Afamin is a new member of the albumin, alpha-fetoprotein, and vitamin D-binding protein gene family. J Biol Chem, 269, 18149-54.
POLKOWSKA, A., PASIEROWSKA, I. E., PASLAWSKA, M., PAWLUCZUK, E. & BOSSOWSKI, A. 2019. Assessment of Serum Concentrations of Adropin, Afamin, and Neudesin in Children with Type 1 Diabetes. Biomed Res Int, 2019, 6128410.
SEEBER, B., MORANDELL, E., LUNGER, F., WILDT, L. & DIEPLINGER, H. 2014. Afamin serum concentrations are associated with insulin resistance and metabolic syndrome in polycystic ovary syndrome. Reprod Biol Endocrinol, 12, 88.
VOS, T., FLAXMAN, A. D., NAGHAVI, M., LOZANO, R., MICHAUD, C., EZZATI, M., SHIBUYA, K., SALOMON, J. A., ABDALLA, S. & ABOYANS, V. J. T. L. 2012. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. 380, 2163-2196.
WANG, W. K., TSAI, C. H., LIU, Y. W., LAI, C. C., HUANG, C. C. & SHEEN-CHEN, S. M. 2020. Afamin expression in breast cancer. Asian J Surg, 43, 750-754.
ZHENG, Y., LEY, S. H. & HU, F. B. 2018. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol, 14, 88-98.
COMPANY, F. T. 2020. Human AFM(Afamin) ELISA Kit [Online]. Available: https://www.fn-test.com/product/eh2493/ [Accessed].
DELHI, N. J. R. T. O. D. M. N. E. N. D. N. D. J. B. M. P. 2012. textbook of diabetes mellitus. 2nd ed, Jaypee Brothers Medical Publishers
DI LEO, G. & SARDANELLI, F. J. E. R. E. 2020. Statistical significance: p value, 0.05 threshold, and applications to radiomics—reasons for a conservative approach. 4, 1-8.
JERKOVIC, L., VOEGELE, A. F., CHWATAL, S., KRONENBERG, F., RADCLIFFE, C. M., WORMALD, M. R., LOBENTANZ, E. M., EZEH, B., ELLER, P., DEJORI, N., DIEPLINGER, B., LOTTSPEICH, F., SATTLER, W., UHR, M., MECHTLER, K., DWEK, R. A., RUDD, P. M., BAIER, G. & DIEPLINGER, H. 2005. Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression. J Proteome Res, 4, 889-99.
KOLLERITS, B., LAMINA, C., HUTH, C., MARQUES-VIDAL, P., KIECHL, S., SEPPALA, I., COOPER, J., HUNT, S. C., MEISINGER, C., HERDER, C., KEDENKO, L., WILLEIT, J., THORAND, B., DAHNHARDT, D., STOCKL, D., WILLEIT, K., RODEN, M., RATHMANN, W., PAULWEBER, B., PETERS, A., KAHONEN, M., LEHTIMAKI, T., RAITAKARI, O. T., HUMPHRIES, S. E., VOLLENWEIDER, P., DIEPLINGER, H. & KRONENBERG, F. 2017. Plasma Concentrations of Afamin Are Associated With Prevalent and Incident Type 2 Diabetes: A Pooled Analysis in More Than 20,000 Individuals. Diabetes Care, 40, 1386-1393.
KONINGER, A., MATHAN, A., MACH, P., FRANK, M., SCHMIDT, B., SCHLEUSSNER, E., KIMMIG, R., GELLHAUS, A. & DIEPLINGER, H. 2018. Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study. Reprod Biol Endocrinol, 16, 30.
KRONENBERG, F. & DIEPLINGER, H. J. C. L. 2015. Afamin is a promising novel marker for metabolic syndrome and related diseases. Clinical Lipidology, 10, 207-3.
KRONENBERG, F., KOLLERITS, B., KIECHL, S., LAMINA, C., KEDENKO, L., MEISINGER, C., WILLEIT, J., HUTH, C., WIETZORREK, G., ALTMANN, M. E., THORAND, B., MELMER, A., DAHNHARDT, D., SANTER, P., RATHMANN, W., PAULWEBER, B., KOENIG, W., PETERS, A., ADHAM, I. M. & DIEPLINGER, H. 2014. Plasma concentrations of afamin are associated with the prevalence and development of metabolic syndrome. Circ Cardiovasc Genet, 7, 822-9.
LESLIE, R. D., PALMER, J., SCHLOOT, N. C. & LERNMARK, A. J. D. 2016. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. 59, 13-20.
LICHENSTEIN, H. S., LYONS, D. E., WURFEL, M. M., JOHNSON, D. A., MCGINLEY, M. D., LEIDLI, J. C., TROLLINGER, D. B., MAYER, J. P., WRIGHT, S. D. & ZUKOWSKI, M. M. 1994. Afamin is a new member of the albumin, alpha-fetoprotein, and vitamin D-binding protein gene family. J Biol Chem, 269, 18149-54.
POLKOWSKA, A., PASIEROWSKA, I. E., PASLAWSKA, M., PAWLUCZUK, E. & BOSSOWSKI, A. 2019. Assessment of Serum Concentrations of Adropin, Afamin, and Neudesin in Children with Type 1 Diabetes. Biomed Res Int, 2019, 6128410.
SEEBER, B., MORANDELL, E., LUNGER, F., WILDT, L. & DIEPLINGER, H. 2014. Afamin serum concentrations are associated with insulin resistance and metabolic syndrome in polycystic ovary syndrome. Reprod Biol Endocrinol, 12, 88.
VOS, T., FLAXMAN, A. D., NAGHAVI, M., LOZANO, R., MICHAUD, C., EZZATI, M., SHIBUYA, K., SALOMON, J. A., ABDALLA, S. & ABOYANS, V. J. T. L. 2012. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. 380, 2163-2196.
WANG, W. K., TSAI, C. H., LIU, Y. W., LAI, C. C., HUANG, C. C. & SHEEN-CHEN, S. M. 2020. Afamin expression in breast cancer. Asian J Surg, 43, 750-754.
ZHENG, Y., LEY, S. H. & HU, F. B. 2018. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol, 14, 88-98.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Rebwar Jalal Ali, Sardar Nouri Ahmed
This work is licensed under a Creative Commons Attribution 4.0 International License.
